Payment overview · 2025
General Payments
$1,712.20
93 reported records · 29 companies
Healthcare provider profile · identity verified
Wei Wei Ma, MD
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · EDISON, NJ · NPI 1063412310
Verified facts
What the public records show
CMS Open Payments records show Wei Wei Ma, MD received $1,712.20 in general payments during 2025 across 93 reported records.
SK Life Science, Inc. accounted for 18.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 37 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Briviact, Gammaked, Panzyga.
Kedrion Biopharma, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GAMMAKED as an associated drug or biological on 761 records involving 541 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Gammaked by this doctor in 2024.
Octapharma USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PANZYGA as an associated drug or biological on 1567 records involving 974 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Panzyga by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GAMMAGARD LIQUID as an associated drug or biological on 29 records involving 8 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Gammagard Liquid by this doctor in 2024.
UCB, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Briviact as an associated drug or biological on 13595 records involving 4444 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Briviact by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$314.97 | 18.4% | 10 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $228.08 | 13.3% | 15 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $158.96 | 9.3% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $155.57 | 9.1% | 13 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $107.24 | 6.3% | 6 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $84.45 | 4.9% | 5 | 2025 |
| Otter Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $62.40 | 3.6% | 4 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $59.28 | 3.5% | 4 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $52.37 | 3.1% | 3 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $52.37 | 3.1% | 3 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $50.49 | 3.0% | 3 | 2025 |
| Aucta Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $41.07 | 2.4% | 4 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $37.69 | 2.2% | 2 | 2025 |
| Octapharma USA, Inc. | Unresolved — no canonical attribution shown | $33.29 | 1.9% | 2 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$32.75 | 1.9% | 2 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $24.00 | 1.4% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $19.84 | 1.2% | 1 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $18.87 | 1.1% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $18.47 | 1.1% | 1 | 2025 |
| Merz Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $18.36 | 1.1% | 1 | 2025 |
| LivaNova USA, Inc. | Unresolved — no canonical attribution shown | $17.98 | 1.1% | 1 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $17.81 | 1.0% | 1 | 2025 |
| SpringWorks Therapeutics, Inc. | Unresolved — no canonical attribution shown | $17.17 | 1.0% | 1 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $15.69 | 0.9% | 1 | 2025 |
| Kedrion Biopharma, Inc. | Unresolved — no canonical attribution shown | $15.47 | 0.9% | 1 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $15.06 | 0.9% | 1 | 2025 |
| CATALYST PHARMACEUTICALS, INC. | Unresolved — no canonical attribution shown | $14.54 | 0.8% | 1 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $14.03 | 0.8% | 1 | 2025 |
| LeMaitre Vascular, Inc. | Unresolved — no canonical attribution shown | $13.93 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,712.20 | 93 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $134.99 | 1 | 2025 |
Source payment records
|
|||||
| Fintepla Normalized: fintepla |
Drug | UCB, Inc. | $111.83 | 6 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $107.24 | 6 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $98.03 | 8 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $84.45 | 5 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $81.80 | 6 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $73.77 | 7 | 2025 |
Source payment records
|
|||||
| SYMPAZAN Normalized: sympazan |
Drug | Otter Pharmaceuticals, LLC | $62.40 | 4 | 2025 |
Source payment records
|
|||||
| Gamunex-C Normalized: gamunex c |
Biological | Grifols USA, LLC | $59.28 | 4 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $52.37 | 3 | 2025 |
Source payment records
|
|||||
| ZEPOSIA Normalized: zeposia |
Drug | Celgene Corporation | $52.37 | 3 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $43.40 | 4 | 2025 |
Source payment records
|
|||||
| Motpoly XR Normalized: motpoly xr |
Drug | Aucta Pharmaceuticals, Inc. | $41.07 | 4 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $37.69 | 2 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | Octapharma USA, Inc. | $33.29 | 2 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $32.75 | 2 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $32.45 | 2 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $25.38 | 2 | 2025 |
Source payment records
|
|||||
| DAYBUE Normalized: daybue |
Drug | ACADIA Pharmaceuticals Inc | $24.00 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $19.84 | 1 | 2025 |
Source payment records
|
|||||
| ONPATTRO Normalized: onpattro |
Drug | Alnylam Pharmaceuticals Inc. | $18.87 | 1 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $18.47 | 1 | 2025 |
Source payment records
|
|||||
| Xeomin Normalized: xeomin |
Biological | Merz Pharmaceuticals, LLC | $18.36 | 1 | 2025 |
Source payment records
|
|||||
| VNS THERAPY SENTIVA MODEL 1000 GENERATOR Normalized: vns therapy sentiva model 1000 generator |
Device | LivaNova USA, Inc. | $17.98 | 1 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $17.81 | 1 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $17.81 | 1 | 2025 |
Source payment records
|
|||||
| GOMEKLI Normalized: gomekli |
Drug | SpringWorks Therapeutics, Inc. | $17.17 | 1 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $15.69 | 1 | 2025 |
Source payment records
|
|||||
| Albuked Normalized: albuked |
Biological | Kedrion Biopharma, Inc. | $15.47 | 1 | 2025 |
Source payment records
|
|||||
| GAMMAKED Normalized: gammaked |
Biological | Kedrion Biopharma, Inc. | $15.47 | 1 | 2025 |
Source payment records
|
|||||
| KEDRAB Normalized: kedrab |
Biological | Kedrion Biopharma, Inc. | $15.47 | 1 | 2025 |
Source payment records
|
|||||
| KOATE Normalized: koate |
Biological | Kedrion Biopharma, Inc. | $15.47 | 1 | 2025 |
Source payment records
|
|||||
| RhoGAM Ultra-Filtered PLUS Normalized: rhogam ultra filtered plus |
Biological | Kedrion Biopharma, Inc. | $15.47 | 1 | 2025 |
Source payment records
|
|||||
| ZEMBRACE SYMTOUCH Normalized: zembrace symtouch |
Drug | Tonix Medicines, Inc. | $15.06 | 1 | 2025 |
Source payment records
|
|||||
| Zilbrysq Normalized: zilbrysq |
Drug | UCB, Inc. | $15.02 | 1 | 2025 |
Source payment records
|
|||||
| FIRDAPSE Normalized: firdapse |
Drug | CATALYST PHARMACEUTICALS, INC. | $14.54 | 1 | 2025 |
Source payment records
|
|||||
| XENOSURE BIOLOGIC PATCH Normalized: xenosure biologic patch |
Device | LeMaitre Vascular, Inc. | $13.93 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Briviact briviact |
2025 | Briviact | 2024 | 61 | exact normalized | Medicare Part D |
| GAMMAKED gammaked |
2025 | Gammaked | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PANZYGA panzyga |
2025 | Panzyga | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Kedrion Biopharma, Inc. Exact reporting entity; no affiliate inference |
2025 | GAMMAKED open payments reported associated product |
CMS Open Payments — General Payments 761 supporting records · 541 recipient NPIs · example record 1206766586 |
Gammaked · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Octapharma USA, Inc. Exact reporting entity; no affiliate inference |
2025 | PANZYGA open payments reported associated product |
CMS Open Payments — General Payments 1567 supporting records · 974 recipient NPIs · example record 1245074635 |
Panzyga · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | GAMMAGARD LIQUID open payments reported associated product |
CMS Open Payments — General Payments 29 supporting records · 8 recipient NPIs · example record 1223786557 |
Gammagard Liquid · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| UCB, Inc. Exact reporting entity; no affiliate inference |
2025 | Briviact open payments reported associated product |
CMS Open Payments — General Payments 13595 supporting records · 4444 recipient NPIs · example record 1224348489 |
Briviact · 2024 Exact normalized brand match · 1 Part D row |
61 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levetiracetam | Levetiracetam | 305 | 102 |
| Lacosamide | Lacosamide | 79 | 27 |
| Lamotrigine | Lamotrigine | 67 | 22 |
| Briviact | Brivaracetam | 61 | 17 |
| Octagam | Immun Globg(Igg)/Malt/Iga Ov50 | 54 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 53 | 15 |
| Divalproex Sodium Er | Divalproex Sodium | 51 | 12 |
| Oxcarbazepine | Oxcarbazepine | 46 | 13 |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 42 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 42 | 11 |
| Panzyga | Immun Glob G(Igg)-Ifas/Glycine | 33 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 32 | suppressed |
| Zonisamide | Zonisamide | 30 | 11 |
| Gammagard Liquid | Immun Glob G(Igg)/Gly/Iga Ov50 | 26 | suppressed |
| Gabapentin | Gabapentin | 24 | suppressed |
| Gammaked | Immune Globul G/Gly/Iga Avg 46 | 24 | suppressed |
| Topiramate | Topiramate | 24 | suppressed |
| Clonazepam | Clonazepam | 23 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 20 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 13 | suppressed |
| Vimpat | Lacosamide | 12 | suppressed |
| Prednisone | Prednisone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,712.20 · 93 records | SK Life Science, Inc. | Albuked, BOTOX, Briviact, DAYBUE, FIRDAPSE, Fintepla, GAMMAKED, GOMEKLI, Gamunex-C, HYQVIA, Hizentra, INGREZZA, KEDRAB, KOATE, Motpoly XR, Nayzilam, ONPATTRO, PANZYGA, QULIPTA, QUTENZA, Qelbree, RhoGAM Ultra-Filtered PLUS, Rystiggo, SYMPAZAN, TYSABRI, UBRELVY, ULTOMIRIS, VALTOCO, VNS THERAPY SENTIVA MODEL 1000 GENERATOR, VUMERITY, VYVGART HYTRULO, WAINUA, XENOSURE BIOLOGIC PATCH, Xeomin, ZEMBRACE SYMTOUCH, ZEPOSIA, Zilbrysq | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Briviact play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Kedrion Biopharma, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error